Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis

Terry Beirn Community Programs for Clinical Research on AIDS

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The effect of fluconazole on the susceptibility of Candida isolates recovered from women infected with human immunodeficiency virus (HIV) was evaluated in a randomized, double-blind, placebo-controlled trial. Women with CD4+ cell counts of ≤ 300 cells/mm3 received either fluconazole (200 mg/week) or placebo as prophylaxis. The antifungal susceptibility of specimens was evaluated. One patient who received fluconazole and 2 patients assigned to placebo had Candida albicans isolates recovered that were resistant to fluconazole (MIC, ≥ 64 μg/mL). Eleven patients assigned fluconazole and 4 patients assigned placebo had non-albicans Candida strains (all Candida glabrata) recovered that were resistant to fluconazole. There was significant azole cross-resistance among the non-albicans Candida species isolates. Although the rate of azole resistance did not significantly increase after fluconazole prophylaxis, there was a trend toward more in vitro azole resistance in C. glabrata isolates from patients assigned fluconazole. Moreover, the majority of resistant vaginal isolates of Candida species were recovered after initiation of open-label fluconazole use.

Original languageEnglish (US)
Pages (from-to)1069-1075
Number of pages7
JournalClinical Infectious Diseases
Volume33
Issue number7
DOIs
StatePublished - Jan 1 2001

Fingerprint

Fluconazole
Candida
HIV
Azoles
Placebos
Candida glabrata
CD4 Lymphocyte Count
Candida albicans

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. / Terry Beirn Community Programs for Clinical Research on AIDS.

In: Clinical Infectious Diseases, Vol. 33, No. 7, 01.01.2001, p. 1069-1075.

Research output: Contribution to journalArticle

@article{4636065a9033438ebc42124d734fab90,
title = "Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis",
abstract = "The effect of fluconazole on the susceptibility of Candida isolates recovered from women infected with human immunodeficiency virus (HIV) was evaluated in a randomized, double-blind, placebo-controlled trial. Women with CD4+ cell counts of ≤ 300 cells/mm3 received either fluconazole (200 mg/week) or placebo as prophylaxis. The antifungal susceptibility of specimens was evaluated. One patient who received fluconazole and 2 patients assigned to placebo had Candida albicans isolates recovered that were resistant to fluconazole (MIC, ≥ 64 μg/mL). Eleven patients assigned fluconazole and 4 patients assigned placebo had non-albicans Candida strains (all Candida glabrata) recovered that were resistant to fluconazole. There was significant azole cross-resistance among the non-albicans Candida species isolates. Although the rate of azole resistance did not significantly increase after fluconazole prophylaxis, there was a trend toward more in vitro azole resistance in C. glabrata isolates from patients assigned fluconazole. Moreover, the majority of resistant vaginal isolates of Candida species were recovered after initiation of open-label fluconazole use.",
author = "{Terry Beirn Community Programs for Clinical Research on AIDS} and Vazquez, {Jose A.} and Vazquez, {Jose Antonio} and Sabel, {Jack D.} and Lynn Steele-Moore and Paula Schuman and William Holloway and Neaton, {James D.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1086/322641",
language = "English (US)",
volume = "33",
pages = "1069--1075",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis

AU - Terry Beirn Community Programs for Clinical Research on AIDS

AU - Vazquez, Jose A.

AU - Vazquez, Jose Antonio

AU - Sabel, Jack D.

AU - Steele-Moore, Lynn

AU - Schuman, Paula

AU - Holloway, William

AU - Neaton, James D.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The effect of fluconazole on the susceptibility of Candida isolates recovered from women infected with human immunodeficiency virus (HIV) was evaluated in a randomized, double-blind, placebo-controlled trial. Women with CD4+ cell counts of ≤ 300 cells/mm3 received either fluconazole (200 mg/week) or placebo as prophylaxis. The antifungal susceptibility of specimens was evaluated. One patient who received fluconazole and 2 patients assigned to placebo had Candida albicans isolates recovered that were resistant to fluconazole (MIC, ≥ 64 μg/mL). Eleven patients assigned fluconazole and 4 patients assigned placebo had non-albicans Candida strains (all Candida glabrata) recovered that were resistant to fluconazole. There was significant azole cross-resistance among the non-albicans Candida species isolates. Although the rate of azole resistance did not significantly increase after fluconazole prophylaxis, there was a trend toward more in vitro azole resistance in C. glabrata isolates from patients assigned fluconazole. Moreover, the majority of resistant vaginal isolates of Candida species were recovered after initiation of open-label fluconazole use.

AB - The effect of fluconazole on the susceptibility of Candida isolates recovered from women infected with human immunodeficiency virus (HIV) was evaluated in a randomized, double-blind, placebo-controlled trial. Women with CD4+ cell counts of ≤ 300 cells/mm3 received either fluconazole (200 mg/week) or placebo as prophylaxis. The antifungal susceptibility of specimens was evaluated. One patient who received fluconazole and 2 patients assigned to placebo had Candida albicans isolates recovered that were resistant to fluconazole (MIC, ≥ 64 μg/mL). Eleven patients assigned fluconazole and 4 patients assigned placebo had non-albicans Candida strains (all Candida glabrata) recovered that were resistant to fluconazole. There was significant azole cross-resistance among the non-albicans Candida species isolates. Although the rate of azole resistance did not significantly increase after fluconazole prophylaxis, there was a trend toward more in vitro azole resistance in C. glabrata isolates from patients assigned fluconazole. Moreover, the majority of resistant vaginal isolates of Candida species were recovered after initiation of open-label fluconazole use.

UR - http://www.scopus.com/inward/record.url?scp=0035478409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035478409&partnerID=8YFLogxK

U2 - 10.1086/322641

DO - 10.1086/322641

M3 - Article

C2 - 11528582

AN - SCOPUS:0035478409

VL - 33

SP - 1069

EP - 1075

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -